Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 6/20 | 0.39 |
| ▸ | ANPEP | P15144 | 5/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16316654 | 1.00 | ATM (0.43) | ATMMMP2ANPEPEPHX2CHRNB2 | |
| SCHEMBL16313088 | 0.83 | ATM (0.42) | ATMMMP2ANPEPCHRNB2CHRNA3 | |
| SCHEMBL16350271 | 0.76 | ATM (0.42) | ATMMMP2ANPEPCHRNB2CHRNA3 | |
| SCHEMBL16300600 | 0.74 | ATM (0.52) | ATMMMP2ANPEPCHRNB2CHRNA3 | |
| SCHEMBL12601580 | 0.74 | ATM (0.47) | ATMMMP2ANPEPCHRNB2CHRNA3 | |
| SCHEMBL16349656 | 0.74 | ATM (0.52) | ATMMMP2ANPEPCHRNB2CHRNA3 | |
| SCHEMBL12562519 | 0.74 | ATM (0.74) | ATMMMP2ANPEPCHRNB2CHRNA3 | |
| SCHEMBL16349658 | 0.74 | ATM (0.47) | ATMMMP2ANPEPCHRNB2CHRNA3 | |
| SCHEMBL16300591 | 0.74 | ATM (0.52) | ATMMMP2ANPEPCHRNB2CHRNA3 | |
| SCHEMBL16300601 | 0.74 | ATM (0.52) | ATMMMP2ANPEPCHRNB2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | ATM 3799/4885MMP2 425/4885ANPEP 22/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | ATM 3799/4885MMP2 425/4885ANPEP 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.